13.01.2011 • NewsPeopleSartoriusMillipore

Dominique Baly Appointed to Sartorius Top Management Team

Former Millipore executive Dominique Baly, has assumed cross-divisional management of marketing, sales and service for the Sartorius laboratory business as president of Sartorius group Laboratory Business.

Dominique Baly, president of Sartorius group Laboratory Business
Dominique Baly, president of Sartorius group Laboratory Business

In this newly created position, he reports to the CEO and is a member of the group executive committee. Sartorius Group highest-level management team is now composed of six individuals, including the executives of both Sartorius AG and the subgroup Sartorius Stedim Biotech.

The company said the new management appointment is a key component in the further strategic and operational development of its laboratory business. The major goals of this initiative are the expansion into strategic, fast growing market segments, the targeted extension of the product portfolio and the reinforcement of direct sales organizations in key markets, the company said in a press release.

Baly has more than 35 years of sales and managerial experience for the U.S.-based pharmaceutical supplier Millipore Corporation, which was acquired by Merck KGaA in 2010. From 2005 to 2008, he was president of the $700 millions Bioscience Division. In 2009, he became CEO of Accelerator Sciences, a U.S. investment firm backed by private equity. Baly is a dual citizen of France and the United States, and holds a degree as a pharmacist from the Louis Pasteur University in Strasbourg, France.

Company

Logo:

Sartorius AG

Otto-Brenner-Str. 20
37079 Göttingen
Germany

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.